Skip to content

Study · Not a test of the peptide alone · 2025

5 results

Long-acting PYY3 -36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.

Wulff BS, Chambers AP, Osorto Contreras CK, Kirkeby K, Rinnov AR, Sustarsic RK, Østergaard S, Laabs JE, O'Neil PM

Obesity (Silver Spring, Md.)8 Jul 2025Cited by 12 (Europe PMC)

PMID40629530 (opens in a new tab)PMCIDPMC12304869 (opens in a new tab)DOI10.1002/oby.24329 (opens in a new tab)PepBankPUB-40629530
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    In a phase 1 study in people with overweight or obesity, all doses of PYY1875 alone and coadministered with semaglutide were tolerated.

    In plain wordsIn a phase 1 study, all doses of PYY1875 alone and given with semaglutide were tolerated.

    Peptide
    Semaglutide
    Outcome
    No significant changeTolerability of PYY1875 alone and with semaglutide (phase 1)
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    In the phase 1 study, all doses of PYY1875 alone and coadministered with semaglutide were tolerated.
    1 context sentence
    Summary · context
    Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In a phase 2 study in people with overweight or obesity, PYY1875 1.0 mg added to semaglutide 2.4 mg had a modest effect versus placebo that was not clinically meaningful.

    In plain wordsIn people with overweight or obesity, adding PYY1875 to semaglutide gave only a small extra effect compared with placebo, not clinically meaningful.

    Peptide
    Semaglutide
    Outcome
    MixedTreatment effect of PYY1875 1.0 mg add-on to semaglutide 2.4 mg (phase 2)
    Study

    n: not reported in source

    Comparator
    Placebo plus semaglutide 2.4 mg
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    In the phase 2 study, a modest but not clinically meaningful treatment effect of PYY1875 1.0 mg versus placebo as an add-on to semaglutide 2.4 mg was observed.
    1 context sentence
    Summary · context
    Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    In a phase 2 study, gastrointestinal adverse events were common with PYY1875 1.0 mg added to semaglutide.

    In plain wordsIn a phase 2 study, stomach and gut side effects were common when PYY1875 1.0 mg was added to semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse events with PYY1875 1.0 mg add-on to semaglutide
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    gastrointestinal-related adverse events were common with the 1.0-mg PYY1875 dose
    1 context sentence
    Summary · context
    Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    In a phase 2 study, the PYY1875 2.0 mg dose escalation regimen added to semaglutide was not tolerated.

    In plain wordsIn a phase 2 study, the 2.0 mg PYY1875 dose escalation given with semaglutide was not tolerated.

    Peptide
    Semaglutide
    Outcome
    Not applicableTolerability of PYY1875 2.0 mg dose escalation add-on to semaglutide
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    the 2.0-mg PYY1875 dose escalation regimen was not tolerated (both as add-ons to semaglutide).
    1 context sentence
    Summary · context
    Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome

    In obese male rats treated with semaglutide, adding the PYY analogue PYY1875 caused additional body weight loss.

    In plain wordsIn rats, adding the PYY analogue PYY1875 to semaglutide caused extra weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight loss with PYY1875 added to semaglutide
    Study

    ratn: not reported in source

    obese male rats
    Comparator
    Semaglutide alone
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    PYY1875 induced additional body weight loss in semaglutide-treated obese rats.
    1 context sentence
    Summary · context
    Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.